HIGHLIGHTS
Quercis Pharma is a late clinical-stage biotech with Phase III assets and strong IP extending through 2045.
Kinisoquin™ is a single oral molecule that acts on thirteen validated targets across thrombosis, inflammation and tumour biology. In the Phase 2 CATIQ study, 57 patients across 11 US sites recorded zero venous thromboembolic events and no major haemorrhage, alongside statistically significant reductions across all key biomarkers: PDI −73%, D-Dimer −22%, sP-selectin −58%. Composition-of-matter protection extends through 2045.
Clinical progress
Phase 3 in cancer-associated thrombosis under an FDA Special Protocol Assessment, with interim data expected Q2 2027.
Multiple assets
Cancer-associated thrombosis, ovarian cancer, refractory solid tumours, sickle cell disease, ALS, COPD and viral disease.
Strong IP
Patent protection extending through 2045 across the platform.
Leadership
A team whose members have guided the approval of more than 50 therapies, spanning global regulatory strategy, development and commercialisation.
Advisors
A Scientific Advisory Board whose members have overseen the registration of 17 cancer drugs, with ties to Harvard, Cornell, ETH Zürich and the Pasteur Institute.
Global mission
Committed to responsible pricing and equitable access wherever patients need these medicines.
Phase 2 results
Zero VTE events and no major bleeding in 57 patients across 11 US sites, with PDI activity reduced 73.3% at the 1,000 mg dose.
Oral, once daily
A single oral capsule, against a standard of care that relies on injectables, infusions and gene therapy.
A clearing field
P-selectin and Factor XI programmes have been withdrawn, halted or failed, leaving few late-stage assets in cancer-associated thrombosis.